What is Idexx Laboratories's market cap?

Idexx Laboratories (IDXX) has a market capitalization of $43.8B and trades on NASDAQ.

What is Idexx Laboratories's revenue and profitability?

Idexx Laboratories generated $4.4B in trailing twelve-month revenue with net income of $1.1B, representing a net margin of 24.6%. Gross margin stands at 62.1%, with free cash flow of $1.1B. These figures are based on the Q1 2026 filing.

Who are Idexx Laboratories's competitors?

Idexx Laboratories's key competitors include Zoetis Inc., Thermo Fisher Scientific Inc., Danaher Corporation, and others. These companies compete in similar markets and product categories.

What subsidiaries does Idexx Laboratories have?

Idexx Laboratories's subsidiaries include ezyVet.

Where is Idexx Laboratories headquartered?

Idexx Laboratories is headquartered in United States of America and employs approximately 11,000 people. It has been publicly traded since 1991.

Idexx Laboratories

IDXX

IDEXX Laboratories is a global leader in the development, manufacture, and distribution of diagnostic products and information technology solutions for the animal health and water testing industries.

Market cap

$43.83B-0.4%

Revenue$4.4B+13.1%

Net income$1.1B+22.4%

Free cash flow$1.1B+27.8%

EPS (diluted)$13.59+25.6%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 5, 2026

Revenue$1.1BBeat by $22.3M EPS$3.47Beat by $0.06

Read the full report

Next report

Aug 4, 2026 (In 3 weeks)

Revenue estimate$1.2B

EPS estimate$3.95

Financials

Q1 2026

Income statement

See full

Revenue$1.1B+14.3%

Gross profit$722.7M+15.9%

Operating income$362.6M+14.5%

Net income$278.4M+14.7%

EPS (diluted)$3.47+17.2%

Balance sheet

See full

Cash & equivalents$200.5M+22.3%

Total debt$575.5M-22.2%

Total equity$1.6B+7.5%

Total assets$3.4B+5.3%

Cash flow

See full

Operating cash flow$266.2M+11.9%

CapEx$32.0M+6.5%

Free cash flow$234.3M+12.7%

Valuation & ratios

Valuation

See full

Market cap$43.83B-0.4%

Enterprise value$44.21B-0.6%

P/E40×-4.6×

P/S9.9×-1.0×

Profitability

See full

Gross margin62.1%+0.8pp

Operating margin31.6%+2.5pp

Net margin24.6%+1.9pp

FCF margin24.4%+2.8pp

Returns & leverage

See full

Return on equity72.9%+13.6pp

Debt / equity0.4×-0.1×

Current ratio1.1×0.0×

Segments

By product

See full

IDEXX VetLab consumables$412.6M+19.7%

Reference laboratory diagnostic and consulting services$386.2M+12.1%

Rapid assay products$84.9M+1.1%

Recurring revenue$73.5M+11.8%

CAG Diagnostics capital - instruments$42.4M+32.7%

By segment

See full

Water segment revenue$50.3M+10.9%

LPD$32.5M+13.6%

Competitors

By market cap

Thermo Fisher Scientific$189.58B+17.0%

Danaher$135.02B-7.2%

Idexx Laboratories$43.8B-0.4%

Agilent Technologies$36.5B+5.7%

Zoetis$31.5B-55.6%

Quest Diagnostics$23.0B+16.7%

Bio-Rad Laboratories$7.6B+11.0%

VolitionRX Limited$16.0M-79.0%

By revenue growth

Idexx Laboratories+13.1%

Quest Diagnostics+11.0%

Agilent Technologies+9.1%

Danaher+4.0%

Zoetis+2.6%

Thermo Fisher Scientific+2.4%

Bio-Rad Laboratories+1.9%

By net margin

Zoetis27.79%+0.9pp

Idexx Laboratories24.63%+1.9pp

Agilent Technologies19.55%+2.0pp

Thermo Fisher Scientific15.19%+0.4pp

Danaher14.89%-0.9pp

Quest Diagnostics9.08%+0.2pp

Bio-Rad Laboratories6.52%+91.7pp

Profile

IDEXX Laboratories is a global leader in the development, manufacture, and distribution of diagnostic products and information technology solutions for the animal health and water testing industries. The company provides a comprehensive ecosystem of point-of-care instruments, reference laboratory services, and practice management software designed to enhance the health and well-being of pets and livestock. Its value proposition centers on integrating diagnostic data through cloud-based platforms and proprietary AI to improve clinical decision-making for veterinarians.

Competitive position

IDEXX is a dominant market leader in the companion animal diagnostics space, leveraging a high-margin recurring revenue model driven by instrument consumables and a massive installed base.

GeographiesNorth America, Europe, Asia-Pacific, Latin America

Customer segmentsVeterinary Practices, Agricultural Producers, Municipalities, Research Laboratories

Business modelRazor-razorblade, Subscription SaaS, Professional Services

SuppliersElectronic component manufacturers, Chemical and reagent suppliers, Logistics and courier services, Cloud infrastructure providers

CustomersVeterinary clinics, Reference laboratories, Public water utilities, Agribusinesses

CountryUnited States of America

Listed1991

Employees11.0K

CEOJonathan J. Mazelsky

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websiteidexx.com

FilingsSEC EDGAR

Ask your AI about Idexx Laboratories.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Idexx Laboratories's market cap?: Idexx Laboratories (IDXX) has a market capitalization of $43.8B and trades on NASDAQ.
What is Idexx Laboratories's revenue and profitability?: Idexx Laboratories generated $4.4B in trailing twelve-month revenue with net income of $1.1B, representing a net margin of 24.6%. Gross margin stands at 62.1%, with free cash flow of $1.1B. These figures are based on the Q1 2026 filing.
Who are Idexx Laboratories's competitors?: Idexx Laboratories's key competitors include Zoetis Inc., Thermo Fisher Scientific Inc., Danaher Corporation, and others. These companies compete in similar markets and product categories.
What subsidiaries does Idexx Laboratories have?: Idexx Laboratories's subsidiaries include ezyVet.
Where is Idexx Laboratories headquartered?: Idexx Laboratories is headquartered in United States of America and employs approximately 11,000 people. It has been publicly traded since 1991.